Short Courses and Special Courses
SC17 – Introducing the WHO 2016 Classification of Testicular Tumors: A Synthesis of Molecular and Morphologic Data
Wednesday, March 21, 2018 - 8:00 am - 12:00 pm
This Short Course session includes up to a one-hour break.
3 CME and 3 SAMs
Daniel M. Berney, FRCPath, St. Bartholomew’s Hospital, London, UK
Muhammad T. Idrees, MD, Indiana University Medical Center, Indianapolis, IN
World Health Organization (WHO) has implemented a new classification of Tumors of the Urinary System and Male Genital Organs in 2016 and the reference text (blue book) was released in January 2016. For testis several modifications in terminologies, novel entities and guidelines are included. The knowledge of this new classification scheme is of utmost importance to deal with diagnostic issues.
The rarity and complexity of testicular tumors present unique challenges for genitourinary pathologists. Even specialized genitourinary pathologists deal with only a handful of cases on annual basis. The spectrum of morphologic variations in testicular tumors is tremendous and poses a great challenge for pathologists especially in general surgical pathology practice because of limited exposure to these rare tumors. Correct diagnosis is the key in clinical management of many of these tumors. High cure rate, especially of germ cell tumors, necessitates having a precise diagnosis in order to administer accurate management plan. Additionally, inherited disorders may be associated with unique morphologic variants which makes it extremely challenging to cater the management in terms of lifelong commitment for the patients and the clinicians. Since the majority of the tumors arising in the testis are in younger patients it places extra stress on surgical pathologists to acquire competency in testicular pathology to avoid the diagnostic pitfalls.
This course will help enhance the diagnostic skills of pathologists, especially genitourinary pathologists who often deal with difficult testicular neoplasms. Since WHO classification is the most followed throughout the world, our effort would be to comprehensively educate pathologists regarding the changes in new classification to streamline the adaptation of this new scheme and in return increase awareness, uniformity and performance.
Upon completion of this educational activity, the learner will be able to:
- Identify the new concepts and entities presented in WHO 2016 classification
- Avoid erroneous interpretations causing difficulties in the clinical management of tumors that may be considerably different if correctly diagnosed
- Present pertinent information in a highly-structured format presenting different challenging diagnostic entities with relevant discussion including differential diagnosis, morphologic mimics, prognostic importance and brief management strategies
Continuing Medical Education and Maintenance of Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 3 SAM credit hours.
Return to 2018 Annual Meeting Short Course Page